Intravenous iron: The latrogenic kick to lose control over oxygen?

Kidney and Blood Pressure Research

Volumn 25, Issue 5, 2002, Pages 284-288

  Deicher, R ^a   Horl W H ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Chronic kidney failure; Iron; Oxidative stress

Indexed keywords

ANTIOXIDANT; IRON; OXIDIZING AGENT; REACTIVE OXYGEN METABOLITE;

ADJUVANT THERAPY; ANEMIA; ANTIOXIDANT ACTIVITY; CELL FUNCTION; CHRONIC KIDNEY DISEASE; CYTOTOXICITY; HEMODIALYSIS PATIENT; HUMAN; IRON THERAPY; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PRIORITY JOURNAL; REVIEW; CHRONIC KIDNEY FAILURE; IATROGENIC DISEASE; INTRAVENOUS DRUG ADMINISTRATION; RENAL REPLACEMENT THERAPY;

ANEMIA; HUMANS; IATROGENIC DISEASE; INJECTIONS, INTRAVENOUS; IRON; KIDNEY FAILURE, CHRONIC; OXIDATIVE STRESS; RENAL DIALYSIS;

EID: 0036432833     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000066793     Document Type: Review

References (51)

1. McCord JM: The evolution of free radicals and oxidative stress. Am J Med 2000;108:652-659.
2. McCord JM, Turrens JF: Mitochondrial injury by ischemia and reperfusion. Curr Top Bioenerg 1994;17:173-195.
3. Betteridge DJ: What is oxidative stress? Metabolism 2000;49(2 suppl 1):3-8.
4. Nguyen AT, Lethias C, Zingraff J, Herbelin A, Naret C, Descamps-Latscha B: Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within microamounts of whole blood. Kidney Int 1985;28:158-167.
5. Himmelfarb J, Lazarus M, Hakim R: Reactive oxygen species production by monocytes and polymorphonuclear leukocytes during dialysis. Am J Kidney Dis 1991;17:271-276.
6. Dasgupta A, Hussain S, Ahmed S: Increased lipid peroxidation in patients on maintenance hemodialysis. Nephron 1992;60:56-59.
7. Loughrey CM, Young IS, Lightbody JH, McMaster D, McNamee PT, Trimble ER: Oxidative stress in haemodialysis. QJM 1994;87: 679-683.
8. Tarng DC, Huang TP, Liu TY, Chen HW, Sung YJ, Wei YH: Effect of vitamin E-bonded membrane on the 8-hydroxy 2′-deoxyguanosine level in leukocyte DNA of hemodialysis patients. Kidney Int 2000;58:790-799.
9. Vlassara H: Serum advanced glycosylation end products: A new class of uremic toxins? Blood Purif 1994;12:54-59.
10. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996;49:1304-1313.
11. Descamps-Latscha B, Witko-Sarsat V: Importance of oxidatively modified proteins in chronic renal failure. Kidney Int Suppl 2001; 78:S108-S113.
12. Nguyen-Khoa T, Massy ZA, De Bandt JP, Kebede M, Salama L, Lambrey G, Witko-Sarsat V, Drueke TB, Lacour B, Thevenin M: Oxidative stress and haemodialysis: Role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 2001;16:335-340.
13. Stenvinkel P, Heimbürger O, Lindholm B, Kaysen G, Bergström J: Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000;15:953-960.
14. Sen CK: Cellular thiols and redox-regulated signal transduction. Curr Top Cell Regul 2000; 36:1-30.
15. Dalton TP, Shertzer HG, Puga A: Regulation of gene expression by reactive oxygen. Annu Rev Pharmacol Toxicol 1999;39:67-101.
16. Abe J, Okuda M, Huang Q, Yoshizumi M, Berk BC: Reactive oxygen species activate p90 ribosomal S6 kinase via fyn and ras. J Biol Chem 2000;275:1739-1748.
17. Janssen-Heininger YM, Macara I, Mossman BT: Cooperativity between oxidants and tumor necrosis factor in the activation of nuclear factor (NF)-kappaB: Requirement of ras/mitogen-activated protein kinases in the activation of NF-kappaB by oxidants. Am J Respir Cell Mol Biol 1999;20:942-952.
18. Herrlich P, Bohmer FD: Redox regulation of signal transduction in mammalian cells. Biochem Pharmacol 2000;59:35-41.
19. Schulze-Osthoff K, Los M, Baeuerle PA: Redox signalling by transcription factors NF-kappaB and AP-1 in lymphocytes. Biochem Pharmacol 1995;50:735-741.
20. Schenk H, Klein M, Erdbrugger W, Droge W, Schultze-Osthoff K: Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-kappaB and AP-1. Proc Natl Acad Sci USA 1994;91:1672-1676.
21. Arrigo AP: Gene expression and the thiol redox state. Free Radic Biol Med 1999;27:936-944.
22. Matthews RJ, Wakasugi N, Virelizier JL, Yodoi J, Hay RT: Thioredoxin regulates the DNA binding activity of NF-kappaB by reduction of a disulphide bond involving cystein 62. Nucleic Acids Res 1992;20:3821-3830.
23. Wei SJ, Botero A, Hirota K, Bradbury CM, Markovina S, Laszlo A, Spitz DR, Goswami PC, Yodoi J, Gius D: Thioredoxin nuclear translocation and interaction with redox factor-1 activates the activator protein-1 transcription factor in response to ionizing radiation. Cancer Res 2000;60:6688-6695.
24. Nordberg J, Arnér ESJ: Reactive oxygen species, antioxidants, and the mammalian thiore-doxin system. Free Radic Biol Med 2001;31: 1287-1312.
25. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, Nguyen AT, Thevenin M, Jaudon MC, Zingraff J, Verger C, Jungers P, Descamps-Lat-scha B: Glutathione antioxidant system as a marker of uremia progression and oxidative stress in chronic renal failure. Free Radic Biol Med 1996;1:845-863.
26. Morena M, Cristol JP, Bosc JY, Tetta C, Forret G, Leger CL, Delcourt C, Papoz L, Descomps B, Canaud B: Convective and diffusive losses of vitamin C during haemodiafiltration session: A contributive factor to oxidative stress in haemodialysis patients. Nephrol Dial Transplant 2002;17:422-427.
27. Nakayama H, Akiyama S, Inagaki M, Gotoh Y, Oguchi K: Dehydroascorbic acid and oxidative stress in haemodialysis patients. Nephrol Dial Transplant 2001;16:574-579.
28. Peuchant E, Carbonneau MA, Dubourg L, Thomas MJ, Perromat A, Vallot C, Clerc M: Lipoperoxidation in plasma and red blood cells of patients undergoing haemodialysis: Vitamins A, E and iron status. Free Radic Biol Med 1994;16:339-346.
29. Saint-Georges MD, Bonnefont DJ, Bourely BA, Jaudon MC, Cereze P, Chaumeil P, Gard C, D'Auzac CL: Correction of selenium deficiency in hemodialyzed patients. Kidney Int Suppl 1989;36:S274-S277.
30. Mimic-Oka J, Simic T, Ekmescic V, Dragicevic P: Erythrocyte glutathione peroxidase and superoxide dismutase activities in different stages of chronic renal failure. Clin Nephrol 1995;44:44-48.
31. Durak I, Akyol O, Basesme E, Canbolat O, Kavutcu M: Reduced erythrocyte defense mechanisms against free radical toxicity in patients with chronic renal failure. Nephron 1994;66:76-80.
32. Linpisarn S, Satoh K, Mikami T, Orimo H, Shinjo S, Yoshio Y: Effects of iron on lipid peroxidation. Int J Hematol 1991;54:181-188.
33. Minotti G, Aust SD: Redox cycling of iron and lipid peroxidation. Lipids 1992;27:219-226.
34. Khoschsorur G, Bratschitsch G, Roob JM, Schaur RJ: Iron-induced lipid peroxidation in whole blood in vitro as determined by malondialdehyde and luminol-enhanced chemiluminescence: Implications for iron supplementation to iron-depleted patients. Med Sci Res 1997;25:389-391.
35. Brown KE, Knudsen CA: Oxidized heme proteins in an animal model of hemochromatosis. Free Radic Biol Med 1998;24:389-391.
36. Roob JM, Khoschsorur G, Tiran A, Horina JH, Holzer H, Winklhofer-Roob B: Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 2000;11:539-549.
37. Herrera J, Nava M, Romero F, Rodriguez-Iturbe B: Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis 2001;37:750-757.
38. Lim PS, Wei YH, Yu YL, Koh B: Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 1999;14:2680-2687.
39. Sunder-Plassmann G, Patruta SI, Hörl WH: Pathobiology of the role of iron in infection. Am J Kidney Dis 1999;34:S25-S29.
40. Patruta SI, Edlinger R, Sunder-Plassmann G, Hörl WH: Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 1998;9:655-663.
41. Banyai S, Rainer V, Derfler K, Druml W, Hörl WH, Sunder-Plassmann G: Bleomycin detectable free iron (BDI) is present in patients on intravenous (iv) iron therapy. J Am Soc Nephrol 1998;9:198A.
42. Pietrangelo A: Physiology of iron transport and the hemochromatosis gene. Am J Physiol Gastrointest Liver Physiol 2002;282:G403-G414.
43. Fillebeen C, Pantopoulos K: Redox control of iron regulatory proteins. Redox Rep 2002;7: 15-22.
44. Topham RW, Walker MC, Calisch MP: Liver xanthine dehydrogenase and iron mobilization. Biochem Biophys Res Commun 1982; 109:1240-1246.
45. 2+ and free iron pool by sulfur amino acid deprivation: The role of ferritin light chain downreg-ulation in prooxidant production. Biochem Pharmacol 2002;63:647-657.
46. Comporti M, Signorini C, Buonocore G, Ciccoli L: Iron release, oxidative stress and erythrocyte ageing. Free Radic Biol Med 2002;32: 568-576.
47. Sommerburg O, Grune T, Hampl H, Riedel E, van Kuijk FJ, Ehrich JH, Siems WG: Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients? Nephrol Dial Transplant 1998;13:2583-2587.
48. Macdougall IC: Intravenous administration of iron in epoetin-treated haemodialysis patients - Which dose, which regimen? Nephrol Dial Transplant 2000;15:1743-1745.
49. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure: European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999;14(suppl 5):1-50.
50. Feldman HI, Santanna J, Guo W, Furst H, Franklin E, Joffe M, Marcus S, Faich G: Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 2002;13: 734-744.
51. Deicher R, Ziai F, Cohen G, Mullner M, Horl WH: High-dose Parenteral Iron Sucrose Depresses Neutrophil Intracellular Killing Capacity. Submitted.